Form 6-K HUTCHMED (China) Ltd For: May 21

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/9/2026

1. USO
2. SPY
3. AMZN
4. GNK
5. FLUT
6. AAPL
7. TMUS
8. AVGO
9. BABA
10. KRUS

May 21, 2026 6:30 AM EDT

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of May 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.

  ​ ​ ​

Description

​

​

​

Exhibit 99.1

​

Press release relating to HUTCHMED and Innovent jointly announce NMPA approval for ELUNATE® (Fruquintinib) in combination with TYVYT® (Sintilimab Injection) for the treatment of patients with locally advanced or metastatic renal cell carcinoma

​

​

​

​

​

​

​

​

​

​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

HUTCHMED (CHINA) LIMITED

​

​

​

​

​

​

​

By:

/s/ Johnny Cheng

​

Name:

Johnny Cheng

​

Title:

Chief Financial Officer

​

​

Date: May 21, 2026

3

ATTACHMENTS / EXHIBITS

EX-99.1


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings